awmsg logo



tenofovir disoproxil fumarate (Viread®)


Reference No. 821

Publication date:
02/11/2011


Appraisal information

tenofovir disoproxil fumarate (Viread®) 245 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 08/09/2011
AWMSG meeting date: 12/10/2011
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1411
Ministerial ratification: 01/11/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tenofovir disoproxil fumarate (Viread®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B (CHB) in adults with decompensated liver disease. Treatment should normally be initiated following dialogue with a specialist liver unit. AWMSG is of the opinion that tenofovir disoproxil fumarate (Viread®) is not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download